{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-051823","form_type":"8-K/A","ticker":"KTTA","cik":"0001841330","company_name":"Pasithea Therapeutics Corp.","filed_at":"2022-08-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.380781+00:00","generated_at":"2026-06-23T20:28:39.284459+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pasithea Therapeutics files Alpha-5 Integrin financials for acquisition closed June 21, 2022","bullets":["Alpha-5 (preclinical-stage, ALS/neuroinflammatory mAbs) had no revenue and $1.7M net loss for FY 2021.","Q1 2022 net loss was $447k; accumulated deficit reached $2.15M as of March 31, 2022.","Total assets $200k, cash & equivalents $122k at March 31, 2022, down from $295k at year-end 2021.","Acquisition closed June 21, 2022; one seller is Pasithea's Executive Chairman and Co-Founder.","Pro forma adjustments deemed immaterial; Alpha-5 became a wholly owned subsidiary of Pasithea."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-051823","json":"https://secwatch.observer/filing/0001213900-22-051823.json","markdown":"https://secwatch.observer/filing/0001213900-22-051823.md","text":"https://secwatch.observer/filing/0001213900-22-051823.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841330/000121390022051823/0001213900-22-051823-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841330/000121390022051823/ea165047-8ka2_pasithea.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T20:28:39.284459+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}